Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment.
Jose Luis Labandeira-GarciaCarmen M LabandeiraRita ValenzuelaMaria A PedrosaAloia QuijanoAna Isabel Rodriguez-PerezPublished in: Biomedicines (2022)
A massive worldwide vaccination campaign constitutes the main tool against the COVID-19 pandemic. However, drug treatments are also necessary. Antivirals are the most frequently considered treatments. However, strategies targeting mechanisms involved in disease aggravation may also be effective. A major role of the tissue renin-angiotensin system (RAS) in the pathophysiology and severity of COVID-19 has been suggested. The main link between RAS and COVID-19 is angiotensin-converting enzyme 2 (ACE2), a central RAS component and the primary binding site for SARS-CoV-2 that facilitates the virus entry into host cells. An initial suggestion that the susceptibility to infection and disease severity may be enhanced by angiotensin type-1 receptor blockers (ARBs) and ACE inhibitors (ACEIs) because they increase ACE2 levels, led to the consideration of discontinuing treatments in thousands of patients. More recent experimental and clinical data indicate that ACEIs and, particularly, ARBs can be beneficial for COVID-19 outcome, both by reducing inflammatory responses and by triggering mechanisms (such as ADAM17 inhibition) counteracting viral entry. Strategies directly activating RAS anti-inflammatory components such as soluble ACE2, Angiotensin 1-7 analogues, and Mas or AT2 receptor agonists may also be beneficial. However, while ACEIs and ARBs are cheap and widely used, the second type of strategies are currently under study.
Keyphrases
- angiotensin converting enzyme
- sars cov
- angiotensin ii
- coronavirus disease
- respiratory syndrome coronavirus
- wild type
- anti inflammatory
- signaling pathway
- end stage renal disease
- induced apoptosis
- emergency department
- cell death
- electronic health record
- machine learning
- deep learning
- cell cycle arrest
- cell proliferation
- oxidative stress
- patient reported